Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_3
1
20%
Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

completed360%
withdrawn120%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_2

RIGENERA 2.0 Trial

NCT02502747
completedphase_2

Sonothrombolysis in Patients With STEMI

NCT03092089
unknown

Imaging and Omics for Cardiovascular Risk During NASA Deep Space Missions

NCT02465554
completedphase_3

Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle

NCT00001891
completedphase_2

Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease

NCT00001889

Clinical Trials (5)

Showing 5 of 5 trials
NCT02502747Phase 2

RIGENERA 2.0 Trial

Withdrawn
NCT03092089Phase 2

Sonothrombolysis in Patients With STEMI

Completed
NCT02465554

Imaging and Omics for Cardiovascular Risk During NASA Deep Space Missions

Unknown
NCT00001891Phase 3

Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle

Completed
NCT00001889Phase 2

Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5